EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study

Wanlong Wu iD, Bingpeng Guo, Wenjia Sun, Dan Chen, Wenwen Xu, Zhiwei Chen, Yakai Fu, Yan Ye, Xia Lyu, Zhixin Xue, Kaiwen Wang, Jiangfeng Zhao und 15 weitere

European Respiratory Journal · 2025-05 · 65 (5) · 2401488

DOI: 10.1183/13993003.01488-2024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Respiratory Journal, online erschienen am 30.01.2025. Verfasst von Wanlong Wu und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Dermatomyositis, Calcineurin Inhibitors, Piperidines. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Hospital Development Center, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the effectiveness and safety of tofacitinib versus calcineurin inhibitor (CNI) as initial immunosuppressive regimen for anti-melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease (MDA5 + DM-ILD).

Methods

Adult Chinese patients with newly diagnosed MDA5 + DM-ILD (ILD course

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialDermatomyositisCalcineurin InhibitorsPiperidinesPyrimidinesImmunosuppressive AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultLung TransplantationInterferon-Induced Helicase, IFIH1Treatment OutcomePropensity ScoreAgedProportional Hazards ModelsProtein Kinase Inhibitors

Substanzen

tofacitinibCalcineurin InhibitorsPiperidinesPyrimidinesInterferon-Induced Helicase, IFIH1IFIH1 protein, humanImmunosuppressive AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
  • Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Rheumatology, Jiading Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Emergency Medicine, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ORCID-Profile: Wanlong Wu

Förderung

  • National Key Research and Development Program of China
  • Shanghai Municipal Hospital Development Center
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Science and Technology Commission of Shanghai Municipal Jiading District
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Wu, W., Guo, B., Sun, W., Chen, D., Xu, W., Chen, Z., Fu, Y., Ye, Y., Lyu, X., Xue, Z., Wang, K., Zhao, J., Xie, C., Chen, Y., Ye, C., Dai, M., Fan, W., Li, J., Wang, X., …, & Ye, S. (2025). Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. European Respiratory Journal, 65(5), 2401488. https://doi.org/10.1183/13993003.01488-2024

Vancouver

Wu W, Guo B, Sun W, Chen D, Xu W, Chen Z, et al. Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study. European Respiratory Journal. 2025;65(5):2401488. doi:10.1183/13993003.01488-2024

BibTeX
@article{Wu2025,
  author = {Wu, Wanlong and Guo, Bingpeng and Sun, Wenjia and Chen, Dan and Xu, Wenwen and Chen, Zhiwei and Fu, Yakai and Ye, Yan and Lyu, Xia and Xue, Zhixin and Wang, Kaiwen and Zhao, Jiangfeng and Xie, Cuiying and Chen, Yi and Ye, Chunhua and Dai, Min and Fan, Wei and Li, Jia and Wang, Xiaodong and Xue, Yu and Wan, Weiguo and Sun, Li and Wu, Huaxiang and Luo, Qun and Han, Qian and Fu, Qiong and Ye, Shuang},
  title = {Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study},
  journal = {European Respiratory Journal},
  year = {2025},
  volume = {65},
  number = {5},
  pages = {2401488},
  doi = {10.1183/13993003.01488-2024}
}
Kostenlos starten →